ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2017

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.

P A Ott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.